Cynthia Butitta Buys Shares in URGN
Cynthia Butitta purchased 8,000 shares of URGN on June 22, 2026.
Key Points
- Cynthia Butitta acquired 8,000 shares of URGN on June 22, 2026, with shares trading near $35.80 on Wednesday.
- RTW Investments holds 4,543,895 shares worth about $81.7 million; BlackRock increased its stake by 244,558 shares to 2,845,567 shares valued at $51.2 million.
- Analysts from HC Wainwright & Co. and Oppenheimer maintain a 'buy' rating on URGN, with price targets of $45 and $40, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Cynthia Butitta, an insider at URGN, purchased 8,000 shares on June 22, 2026. This transaction was not part of a pre-planned trading strategy and was reported with the transaction code 'A'. On Wednesday, URGN shares traded around $35.80.
Other Institutional Activity in URGN
RTW Investments, LP holds a significant stake in URGN with 4,543,895 shares worth approximately $81.7 million, maintaining its position without any change in shares. BlackRock, Inc. increased its holdings by 244,558 shares, bringing its total to 2,845,567 shares valued at $51.2 million, marking a 9.4% increase. Toronto Dominion Bank opened a new position with 2,616,714 shares, valued at $47.0 million. Morgan Stanley slightly reduced its stake by 2,863 shares to 2,560,038 shares, valued at $46.0 million. Kynam Capital Management, LP also opened a new position, acquiring 2,247,393 shares worth about $40.4 million.
Insider Buying and Selling at UroGen Pharma Ltd.
On June 22, 2026, several insiders at URGN bought shares. Robinson James Jr. acquired 8,000 shares and an additional 10,000 shares. Wen Leana purchased 10,000 shares, while Belldegrun Arie bought 20,000 shares. Butitta Cynthia also acquired 10,000 shares, and Wildman Daniel George bought 10,000 shares. All these purchases were not made under Rule 10b5-1 plans.
Analysts Set New Price Targets
On May 11, 2026, HC Wainwright & Co. maintained a 'buy' rating on URGN with a price target of $45. Oppenheimer also maintained a 'buy' rating with a $40 price target on May 7, 2026. The analyst consensus remains strong with a 'buy' recommendation, supported by multiple firms.
Bottom Line
Cynthia Butitta's recent purchase of URGN shares is a notable insider transaction. Institutional investors like BlackRock have increased their stakes, indicating interest in the company. Analysts continue to support URGN with 'buy' ratings and optimistic price targets. As always, remember that insider and institutional transactions provide a snapshot of past activity and may not reflect current positions.
Get UroGen Pharma Ltd. alerts
New 13F filings, insider trades, and analyst moves on $URGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.